Glypican-3 as a Theranostic Target in Hepatocellular Carcinoma. (PubMed, J Nucl Med) - Sep 25, 2026 - "A clinical phase 1 trial with an 225Ac-labeled macrocyclic peptide ([225Ac]Ac-RAYZ-8009, RYZ801) using PET with [68Ga]Ga-RAYZ-8009 (RYZ811) for patient selection is currently ongoing. Furthermore, an 225Ac-labeled GPC3 antibody, BAY 3547926, is undergoing phase 1/2 clinical testing."
First-in-human • IO biomarker • Journal • Fibrosis • Hepatoblastoma • Hepatocellular Cancer • Immunology • Oncology • Solid Tumor • GPC3
|
|
Constantin Lapa; Matthias Eiber; Ursula Ehmer; Wolfgang A Weber
|